Physicians in fields like cardiology have traditionally looked to clinical practice guidelines to help articulate the best evidence-based care for patients. The rapidly growing movement to value-based care is prompting clinicians—including echocardiographers—to carefully weigh a more focused and integrative approach to delivering consistent, quality medicine: care pathways.

The American Society of Nuclear Cardiology (ASNC) kicked off a three-day conference in Rosemont, Illinois, April 21, an event that attracts cardiologists from all over the country.

Patients at Terrebonne General Medical Center (TGMC) now have access to safe, high-quality interventional cardiac exams with the installation of Toshiba Medical’s InfinixTM-i Sky +. TGMC, a nationally recognized healthcare organization and home to one of the most advanced vascular interventional practices in the country, is the first healthcare provider in the United States to install the Infinix-i Sky +.

Many of the world’s leading interventional cardiologists and cardiovascular professionals will gather in New Orleans May 10-13 for the 40th Annual Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. The meeting coincides with the 40thanniversary of the first coronary angioplasty, a procedure that revolutionized medicine.

The U.S. Food and Drug Administration (FDA) has approved Cardiac Insight’s wearable electrocardiogram sensor, a device that provides physicians with immediate access to improved reporting and analysis of heartbeat data.

Adults who had two or more midlife vascular risk factors had a significantly increased risk of elevated amyloid deposition in the brain later in life compared with those with no midlife vascular risk factors, according to a prospective cohort study.

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for arrhythmia detection.

Treating today’s cancer patient no longer means simply targeting the cancer. Given the known cardiotoxicities of some established chemotherapies and the possibility that newer approaches may damage the heart, oncologists, cardiologists and imaging specialists now work together to detect and minimize the risk of treatment-induced heart failure.